Cardiovascular disease is the leading cause of death in Fabry disease patients.¹ Undiagnosed and untreated Fabry disease leads to progressive, irreversible, life-threatening heart injury.^2,3

Think Fabry, think renal involvement that may present early in life and could go undetected.

Think Fabry, think screening at-risk family members.¹

Think Fabry, think early treatment to help slow or prevent life-threatening disease progression.^1,2

Beyfortus^® är den första och enda RSV-immuniseringen designad för alla spädbarn, för skydd mot RSV-sjukdom i de nedre luftvägarna (LRTD).¹

A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/ without prior use of glucagon-like peptide-1 receptor agonist therapy.¹

A podcast series designed by cardiologists, for cardiologists and other healthcare professionals.

Toujeo is a 2nd generation, long-acting insulin analog containing insulin glargine 300 units/mL. Toujeo® lowers blood glucose levels evenly over a long period of time. It therefore only needs to be administered once a day.

Toujeo is a 2nd generation, long-acting insulin analog containing insulin glargine 300 units/mL. Toujeo® is available in two prefilled pens. See how Toujeo® is administrated In six simple steps and watch instructional video.

Beneath the skin of patients with AD—type 2 inflammation and the cytokines involved.

Being diagnosed with type 1 diabetes at the age of 18 is a life-altering experience for most people. But when, like Lucas, you receive three other diagnoses within a few months, it can feel overwhelming. Living with type 1 diabetes becomes even more challenging when you also have autism.

Three years ago, Tina’s 13-year-old son was diagnosed with type 1 diabetes. It was a harrowing ordeal, as he was rushed to the hospital with severe diabetic ketoacidosis. Even today, the entire family remains deeply affected by the traumatic experience.